The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

CD30-directed Antibody-Tripeptide MMAE Conjugate

Important Notice Regarding the Scientific Information You Have Requested

You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.

Please acknowledge that you understand this before proceeding.

Back

Molecule overview Clinical trials Scientific presentations

CD30-directed Antibody-Tripeptide MMAE Conjugate

PF-08046045 is an investigational compound. Its safety and efficacy have not been established

Overview + Rationale Mechanism of Action Stage of Development

Share to an HCP

Overview + Rationale

PF-08046045 is a CD30-directed ADC and utilizes the novel cleavable tripeptide linker.¹
CD30 is expressed in many B- and T-cell lymphomas while having limited expression in normal tissue²

Mechanism of Action

Stage of Development

small icon representing hematologic cancer

Lymphomas

Phase 1 Monotherapy

CD30-directed Antibody-Tripeptide MMAE Conjugate

Geo Regions

CD30-directed Antibody-Tripeptide MMAE Conjugate

Overview + Rationale

Mechanism of Action

Stage of Development

Lymphomas

This information is current as of August 5th 2025.